CODIAK BIOSCIENCES INC (CDAK) Stock Price, Quote, News and Overview
NASDAQ:CDAK - Nasdaq - US1920101060 - Common Stock - Currency: USD
CDAK Quote, Performance and Key Statistics
0.057
-0.07 (-55.98%)
The current stock price of CDAK is 0.057 USD. In the past month the price decreased by -90.17%. In the past year, price decreased by -99%.
CDAK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.6 | 366.73B | ||
| AMGN | AMGEN INC | 13.6 | 159.54B | ||
| GILD | GILEAD SCIENCES INC | 15.32 | 147.52B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.3 | 101.34B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.8 | 63.05B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.29B | ||
| ARGX | ARGENX SE - ADR | 71.6 | 40.62B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 35.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.28B | ||
| INSM | INSMED INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 22.31B | ||
| BIIB | BIOGEN INC | 8.67 | 20.33B |
Related stock screener links
About CDAK
Company Profile
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
Company Info
CODIAK BIOSCIENCES INC
35 Cambridgepark Drive, Suite 500
Cambridge MASSACHUSETTS 02140 US
CEO: Douglas E. Williams
Employees: 102
Phone: 16179494100.0
CODIAK BIOSCIENCES INC / CDAK FAQ
What is the stock price of CODIAK BIOSCIENCES INC today?
The current stock price of CDAK is 0.057 USD. The price decreased by -55.98% in the last trading session.
What is the ticker symbol for CODIAK BIOSCIENCES INC stock?
The exchange symbol of CODIAK BIOSCIENCES INC is CDAK and it is listed on the Nasdaq exchange.
On which exchange is CDAK stock listed?
CDAK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CODIAK BIOSCIENCES INC stock?
7 analysts have analysed CDAK and the average price target is 9.18 USD. This implies a price increase of 16005.26% is expected in the next year compared to the current price of 0.057. Check the CODIAK BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CODIAK BIOSCIENCES INC worth?
CODIAK BIOSCIENCES INC (CDAK) has a market capitalization of 2.10M USD. This makes CDAK a Nano Cap stock.
How many employees does CODIAK BIOSCIENCES INC have?
CODIAK BIOSCIENCES INC (CDAK) currently has 102 employees.
Is CODIAK BIOSCIENCES INC (CDAK) expected to grow?
The Revenue of CODIAK BIOSCIENCES INC (CDAK) is expected to grow by 61.58% in the next year. Check the estimates tab for more information on the CDAK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CODIAK BIOSCIENCES INC (CDAK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CDAK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CDAK, evaluating the profitability, health, valuation and growth aspects
- CODIAK BIOSCIENCES INC (CDAK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CODIAK BIOSCIENCES INC (CDAK) Sales and EPS estimates to see what analysts future expectations are.
- CODIAK BIOSCIENCES INC (CDAK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CODIAK BIOSCIENCES INC (CDAK) Insider and Institutional Ownership to learn about the owners and their transactions.
- CODIAK BIOSCIENCES INC (CDAK) Stock Chart to make your own analysis
- CODIAK BIOSCIENCES INC (CDAK) Latest news and press-releases to stay up to date.
Does CODIAK BIOSCIENCES INC (CDAK) stock pay dividends?
CDAK does not pay a dividend.
When does CODIAK BIOSCIENCES INC (CDAK) report earnings?
CODIAK BIOSCIENCES INC (CDAK) will report earnings on 2023-05-03.
What is the Price/Earnings (PE) ratio of CODIAK BIOSCIENCES INC (CDAK)?
CODIAK BIOSCIENCES INC (CDAK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.99).
CDAK Technical Analysis
CDAK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDAK. Both the profitability and financial health of CDAK have multiple concerns.
CDAK Financial Highlights
Over the last trailing twelve months CDAK reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 44.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.66 |
CDAK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CDAK. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 41.06% and a revenue growth 61.58% for CDAK